Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial

BACKGROUND: These subgroup analyses of a Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of erenumab 70 mg in Japanese migraine patients with/without prior preventive treatment failure(s) (“failed-yes” and “failed-no” subgroups) and with/without concomit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirata, Koichi, Sakai, Fumihiko, Takeshima, Takao, Imai, Noboru, Matsumori, Yasuhiko, Yoshida, Ryuji, Numachi, Yotaro, Peng, Cheng, Mikol, Daniel D., Cheng, Sunfa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449906/
https://www.ncbi.nlm.nih.gov/pubmed/34537006
http://dx.doi.org/10.1186/s10194-021-01313-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449906/
https://www.ncbi.nlm.nih.gov/pubmed/34537006
http://dx.doi.org/10.1186/s10194-021-01313-8

Ejemplares similares